Symptoms and General Pathology

All Conditions

Diseases and Abnormalities at or Before Birth

Digestive System Diseases

Heart and Blood Diseases

Blood and Lymph Conditions

Neoplasms

Rare Diseases

Hemorrhage

Congenital Abnormalities

Gastrointestinal Hemorrhage

Telangiectasis

Arteriovenous Malformations

Telangiectasia, Hereditary Hemorrhagic

Angiodysplasia

Melena

Hemangioma

Vascular Diseases

Gastrointestinal Diseases

Vascular Malformations

Cardiovascular Abnormalities

Neoplasms, Vascular Tissue

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Hematologic Diseases

Hereditary Hemorrhagic Telangiectasia

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Thalidomide

Immunosuppressive Agents

Immunologic Factors

Anti-Bacterial Agents

Angiogenesis Inhibitors

Growth Inhibitors

Atul Kumar, MD

James Gossage, MD

The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.

Arteriovenous malformations (AVM's) are the commonest vascular abnormalities of the gut. AVM's or Angiodysplasia may be acquired or inherited as in a hereditary hemorrhagic telangiectasia (HHT). Repeated episodes of gastrointestinal bleeding (GIB), especially in the elderly have been attributed to angiodysplasia. Clinically significant GIB may be also seen in up to 40% of HHT patients, usually in the fourth and fifth decades of life. GIB may manifest both as acute major hemorrhage, slow intermittent blood loss or a combination of these findings and patients may be symptomless, present with acute bleeding or iron deficiency anemia. Recurrent hemorrhage and persistent iron-deficiency anemia is common despite supplemental iron therapy and patients require repeated transfusions. Amongst patients with preexisting co-morbidities, repeated bleeding may lead to significant morbidity and mortality. Furthermore, re-bleeding among these patients consumes a disproportionate share of healthcare resources devoted to multiple admissions, repeated endoscopies and blood transfusions. There are no effective treatment options available currently. The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.

Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

Augusta University

University of Massachusetts, Worcester

Northport Veterans Affairs Medical Center

Atul Kumar

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	NCT00389935	Arteriovenous M... Hereditary Hemo... Hematochezia Melena	Thalidomide	18 Years -	Northport Veterans Affairs Medical Center
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	NCT00389935	Arteriovenous M... Hereditary Hemo... Hematochezia Melena	Thalidomide	18 Years -	Northport Veterans Affairs Medical Center

Spots Global Cancer Trial Database for hematochezia

Every month we try and update this database with for hematochezia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.